180 related articles for article (PubMed ID: 33397002)
1. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
2. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
Huang JB; Jiang L; Chen C; Xue HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
5. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
6. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
7. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
[TBL] [Abstract][Full Text] [Related]
8. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
9. Clinical Research of Pulmonary Langerhans Cell Histiocytosis in Children.
Wang D; Cui L; Li ZG; Zhang L; Lian HY; Ma HH; Zhao YZ; Zhao XX; Wang TY; Zhang R
Chin Med J (Engl); 2018 Aug; 131(15):1793-1798. PubMed ID: 30058575
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis of 26 children with postoperative residual or recurrent fibrosarcoma].
Tang JJ; Pan C; Gao YJ; Han YL; Hu WT; Zhang J; Zhou M; Tang JY
Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):668-673. PubMed ID: 32842388
[No Abstract] [Full Text] [Related]
12. Pediatric pulmonary multisystem langerhans cell histiocytosis: does lung lesion severity affect the outcome?
Sedky M; Gohar S; Ahmed S; Zaky I; Salama A; Hassanein O; Maher E; ElHaddad A
Orphanet J Rare Dis; 2023 Nov; 18(1):361. PubMed ID: 37978394
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
14. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
15. Langerhans Cell Histiocytosis: Single Center Experience of 25 Years.
Tuysuz G; Yildiz I; Ozdemir N; Adaletli I; Kurugoglu S; Apak H; Dervisoglu S; Bozkurt S; Celkan T
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019035. PubMed ID: 31205639
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognosis of Langerhans cell histiocytosis in children: an analysis of 34 cases].
Li D; Li H; Shi H
Zhongguo Dang Dai Er Ke Za Zhi; 2017 Jun; 19(6):627-631. PubMed ID: 28606227
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland.
Raciborska A; Bilska K; Węcławek-Tompol J; Gryniewicz-Kwiatkowska O; Hnatko-Kołacz M; Stefanowicz J; Pieczonka A; Jankowska K; Pierelejewski F; Ociepa T; Sobol-Milejska G; Muszyńska-Rosłan K; Michoń O; Badowska W; Radwańska M; Drabko K
BMC Cancer; 2020 Sep; 20(1):874. PubMed ID: 32917181
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.
Kim BE; Koh KN; Suh JK; Im HJ; Song JS; Lee JW; Kang HJ; Park KD; Shin HY; Choi HS; Lee SH; Yoo KH; Sung KW; Koo HH; Jung HL; Chung NG; Cho B; Kim HK; Lyu CJ; Baek HJ; Kook H; Park JE; Park HJ; Park BK; Yoo ES; Ryu KH; Lee KS; Kim HS; Lee JM; Park ES; Yoon HS; Lee KC; Lee MJ; Lim YT; Kim HM; Park SK; Park JA; Kim SK; Park M; Lim YJ; Lee YH; Seo JJ;
J Pediatr Hematol Oncol; 2014 Mar; 36(2):125-33. PubMed ID: 24276037
[TBL] [Abstract][Full Text] [Related]
20. Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis.
Minkov M; Pötschger U; Thacker N; Astigarraga I; Braier J; Donadieu J; Henter JI; Lehrnbecher T; Rodriguez-Galindo C; Sieni E; Nanduri V; van den Bos C; Abla O;
J Pediatr; 2021 Oct; 237():65-70.e3. PubMed ID: 34146548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
